Qureight, a techbio company advancing the understanding of lung and heart disease through application of its AI-powered ...
Study published in ‘American Journal of Respiratory Cell and Molecular Biology’ validates Qureight’s deep-learning models and imaging platform beyond fibrotic lung disease, into new therapeutic areas ...
MedPage Today on MSN
Could This Be the First Disease-Modifying Drug in Bronchiectasis?
CHICAGO -- Brensocatib (Brinsupri) appeared to have a disease-modifying effect on structural lung changes in non-cystic ...
Ensifentrine significantly improved lung function after 12 weeks in patients with moderate to severe COPD with and without ...
Technique may enable doctors to rescue patients whose airways are blocked by injury or inflammation or whose lung function is ...
BridgeBio Pharma said on Monday its experimental drug for a rare muscle disorder, which currently has no approved treatments, showed improvements in motor and lung function in a late-stage trial, ...
Providence Holy Cross Medical Center is the first Providence hospital in the San Fernando Valley to offer a minimally ...
The complications highlight pregnancy as a crucial life opportunity for CV health optimization, said investigators led by ...
BridgeBio Pharma said on Monday its experimental drug for a rare muscle disorder, which currently has no approved treatments, showed improvements in motor and lung function in a late-stage trial. The ...
Think you’re too old to quit smoking? Leaving behind cigarettes can be good for your cognitive abilities, hearing, seeing, ...
Arcturus Therapeutics shares plunged 56% after Phase 2 cystic fibrosis trial data showed no meaningful lung function ...
AIET cell therapy prolongs survival of cancer patients in Vinmec Hospital, Vietnam, with tech-transfer by GN Corporation & ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback